Exicure completes the last patient, last visit in phase 2 study of GPC-100 for stem cell mobilization in multiple myeloma patients undergoing autologous transplant

Exicure, Inc., a clinical-stage biotechnology company developing therapeutics for hematologic diseases, announced it has completed the last patient, last visit in its ongoing phase 2 clinical trial (NCT05561751)

To access the full article, please log in or subscribe.